Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
Erasca to Present at Upcoming Conferences in November
Erasca (ERAS), What Is Driving Attention Around The Stock Today?
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
Erasca, Inc.: The Discount RevMed?
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20
Guggenheim Maintains Buy on Erasca, Raises Price Target to $21
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.